Document Detail

Increased expression of p27 is associated with the cisplatin resistance in gastric cancer cell line YCC-3.
MedLine Citation:
PMID:  20661724     Owner:  NLM     Status:  In-Process    
The major obstacle of treating cancer patients is acquisition of chemoresistance, in which treated tumor cells become insensitive after chronic drug exposure. To study the mechanism of acquired cisplatin resistance, we established a cisplatin-resistant human gastric cancer cell line. The cisplatin-resistant cell line (YCC-3/R) was isolated after exposing the gastric cancer cell line, YCC-3, to a constant concentration (0.5 microg/mL) of cisplatin for 12 months. The expression of cell cycle regulatory proteins (p53, Bax, p21, p27) in the YCC-3/R were investigated by western blot analysis. The cisplatin treatment significantly down-regulated the p53 and p21 expression level, while up-regulated the p27 expression in the YCC-3/R cells compared to the parental cells. The Bax expression level was similar in both cells. These results suggest that the p27 dependent-cell cycle arrest may prevent cisplatin-induced apoptosis and give enough time to repair the DNA damage in the YCC-3/R cells.
Tuong Vy Thi Le; Youngcheol Seo; Chun Jeih Ryu; Hye Ran Lee; Hyun-Ju Park
Related Documents :
2168554 - Reconstituted basement membrane (matrigel) and laminin can enhance the tumorigenicity a...
2915574 - Increased sensitivity to 1-beta-d-arabinofuranosylcytosine in p388 murine leukemic cell...
2550374 - Oestrogen potentiates topoisomerase-ii-mediated cytotoxicity in an activated subpopulat...
18162584 - Stard13(dlc-2) rhogap mediates ceramide activation of phosphatidylglycerolphosphate syn...
10902814 - Localization in tissues and secretion of eotaxin by cells from normal endometrium and e...
19642814 - The number of cd68(+) (hofbauer) cells is decreased in placentas with chorioamnionitis ...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-07-27
Journal Detail:
Title:  Archives of pharmacal research     Volume:  33     ISSN:  0253-6269     ISO Abbreviation:  Arch. Pharm. Res.     Publication Date:  2010 Jul 
Date Detail:
Created Date:  2010-07-27     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8000036     Medline TA:  Arch Pharm Res     Country:  Korea (South)    
Other Details:
Languages:  eng     Pagination:  1127-32     Citation Subset:  IM    
Sungkyunkwan University, Suwon, Korea.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The phosphoinositide-3-kinase/Akt pathway mediates the transient increase in Nanog expression during...
Next Document:  Praying for healthy minds and healthy bodies in ICU survivors.